Nahi et al [48] found evidence of dose-dependent apoptosis and cytotoxicity in CLL cells and suggested that ZNF331 is a small molecule that targets TP53, which could be useful for the treatment of drug-resistant leukemia. Here, ZNF331 is linked to leukemia.